Nilotinib therapy of chronic myeloid leukemia (CML) is associated with acceleration of atherosclerosis.
Nilotinib is a potent second-generation BCR/ABL1 inhibitor (tyrosine kinase inhibitor). It affects endothelial cells and induces a pro-atherogenic state.
Sites of atherosclerosis include:
(1) coronary arteries
(2) cerebrovascular disease
(3) peripheral artery occlusive disease
The effect can be seen even after relatively short-term therapy.
Patients do not show an increase in venous thromboembolic events.
To read more or access our algorithms and calculators, please log in or register.
